425 related articles for article (PubMed ID: 28836957)
1. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.
Earley W; Durgam S; Lu K; Debelle M; Laszlovszky I; Vieta E; Yatham LN
J Affect Disord; 2017 Jun; 215():205-212. PubMed ID: 28343051
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
[TBL] [Abstract][Full Text] [Related]
6. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies.
Barabássy Á; Sebe B; Acsai K; Laszlovszky I; Szatmári B; Earley WR; Németh G
Neuropsychiatr Dis Treat; 2021; 17():957-970. PubMed ID: 33854317
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
Lao KS; He Y; Wong IC; Besag FM; Chan EW
CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
[TBL] [Abstract][Full Text] [Related]
10. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression.
Earley WR; Burgess M; Rekeda L; Hankinson A; McIntyre RS; Suppes T; Calabrese JR; Yatham LN
J Affect Disord; 2020 Feb; 263():386-395. PubMed ID: 31969269
[TBL] [Abstract][Full Text] [Related]
11. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.
Durgam S; Earley W; Li R; Li D; Lu K; Laszlovszky I; Fleischhacker WW; Nasrallah HA
Schizophr Res; 2016 Oct; 176(2-3):264-271. PubMed ID: 27427558
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
13. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
Laszlovszky I; Barabássy Á; Németh G
Adv Ther; 2021 Jul; 38(7):3652-3673. PubMed ID: 34091867
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
Kane JM; Zukin S; Wang Y; Lu K; Ruth A; Nagy K; Laszlovszky I; Durgam S
J Clin Psychopharmacol; 2015 Aug; 35(4):367-73. PubMed ID: 26075487
[TBL] [Abstract][Full Text] [Related]
17. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
[TBL] [Abstract][Full Text] [Related]
18. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
[TBL] [Abstract][Full Text] [Related]
19. Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression.
Citrome L; Yatham LN; Patel MD; Barabássy Á; Hankinson A; Earley WR
J Affect Disord; 2021 Jun; 288():191-198. PubMed ID: 33915374
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder.
Vieta E; Earley WR; Burgess MV; Durgam S; Chen C; Zhong Y; Barabássy Á; Németh G
Int Clin Psychopharmacol; 2019 Mar; 34(2):76-83. PubMed ID: 30531358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
